ArticleFrontiers in immunology2023

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.

James M Lonie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.